Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
139
resultados
Última actualización
16/11/2025 [07:03:00]
Resumen de: AU2024271182A1
The present invention relates to the use of the HIP/PAP protein, or a derivative thereof, in the treatment and prevention, and in particular in the treatment, of a cognitive disorder associated with anxiety disorder(s) in an individual in need thereof, as well as for improving cognition in an individual affected by a neurological disorder associated with anxiety disorder(s) or for alleviating cognitive deficit in an individual affected by a disorder selected from the group consisting of Obsessive-compulsive disorder, Attention deficit disorder, Dementia with Lewy bodies disease, Early onset dementia, Epilepsy-related cognitive dysfunction, Fronto-temporal dementia, Posterior cortical atrophy, Huntington's disease (HD), Parkinson's disease, bipolar disorder, substance abuse, attention deficit disorders, psychotic disorders and a sars-cov-2 infection, and also in the prevention and/or treatment of diet induced cognitive and anxiety deficits in an individual in need thereof, and in particular high fat diet induced cognitive and anxiety deficits.
Resumen de: US2025345415A1
The present disclosure describes, inter alia, fusion polypeptides comprising a SARS-CoV-2 Spike polypeptide fragment comprising at least a portion of the N-terminal domain, domains CD1, RBM, and CD2, and at least a portion of CTD1, wherein the N- or C-terminus of the Spike polypeptide fragment is fused to a heterologous N- or C-terminal tag comprising at least two, at least three, or at least four amino acids, as well as polynucleotides and vectors expressing such fusion polypeptides, pharmaceutical compositions comprising the polypeptides or polynucleotides encoding them, host cells for their production, and methods of using such pharmaceutical compositions as vaccines or for generation of antibodies.
Resumen de: US2025345413A1
An immunogenic subunit vaccine antigen which comprises at least two receptor-binding domains (RBDs) of the spike (S) protein of SARS-CoV-2 which are fused to a heterologous immunogenic carrier protein, wherein each of said at least two RBDs has a folded structure in an accessible conformation to bind the human angiotensin-converting enzyme 2 (ACE2) receptor protein.
Resumen de: US2025345408A1
The invention relates, in part, to a method for the prophylactic treatment of a coronavirus infection in a human adult subject comprising administering at least two doses of a Bacillus Calmette-Guerin (BCG) vaccine to the subject, wherein the subject is a type I diabetic.
Resumen de: US2025345307A1
Described herein are compositions, uses thereof, and methods for treating a viral infection in a host cell or organism infected by the virus, such as coronaviruses (e.g., severe acute respiratory syndrome coronavirus SARS-CoV, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2, the virus and its mutant forms that cause COVID-19, Middle East respiratory syndrome coronavirus MERS-CoV), Zika virus, Lassa virus, Crimean Congo hemorrhagic fever virus, hepatitis E virus, and other RNA viruses. Also described herein are synthetic rocaglate compositions, uses thereof, and methods for reducing or inhibiting translation initiation of a messenger ribonucleic acid (mRNA) of a virus in a host cell or organism infected by the virus.
Resumen de: US2025347699A1
This disclosure relates to a method of expressing the receptor-binding domain (RBD) region of the coronavirus SARS-CoV-2 Spike protein in a highly native form that is strongly reactive to natural antibodies induced upon SARS-CoV-2 infection or vaccination of humans and that more efficiently binds the angiotensin-converting enzyme 2 (ACE2) receptor. This method fuses the RBD to the C-terminus of an N-terminal fragment of the gp70 protein (the surface protein (SU) of the Friend57 strain of murine leukemia viruses). This method of expression enhances the native folding of the RBD and increases its recognition by antibodies present in immune sera and its ability to interact with the ACE2 receptor. Further disclosed are methods of using this form of RBD for various purposes.
Resumen de: US2025344786A1
Disclosed herein are protective apparatuses for minimizing the risk of transmission of SARS-CoV-2 and other infectious diseases between individuals in close proximity to one another. Said apparatuses may comprise a receiving component comprising a first aperture comprising a series of flanges; as well as a substantially transparent shield component. Protective apparatuses of the present disclosure may be used to protect dentists and other healthcare workers from transmission of infectious agents and likewise may be used to protect patients in the same manner. Also disclosed herein are systems comprising such protective apparatuses installed to a substantially cylindrical suctioning device such as a vacuum hose or operatively attached to an articulating mechanical arm. Also disclosed herein are methods of using such protective apparatuses and systems to mitigate the risk of transmission of infectious diseases between, without limitation, patients and healthcare workers treating such patients.
Resumen de: US2025346615A1
Glycerophosphoinositol (GPI) is used in preventing and treating COVID-19 infections. An environmentally sustainable method is for obtaining glycerophosphoinositol. In particular, a process for preparing glycerophosphoinositol from crude or partially purified phospholipid mixtures, includes in sequence: a) hydrolysis of a crude or partially purified phospholipid mixture by treatment with PLA1 and PLA2 enzymes; b) microfiltration of the mixture from step a) and subsequent ultrafiltration and nanofiltration of the microfiltrate to give a concentrated aqueous fraction of reaction products; c) electrodialysis of the aqueous fraction of step b) for separating ionic compounds from neutral compounds; d) ion exchange chromatography. Moreover, glycerophosphoinositol is used in preventing and treating a COVID-19 syndrome.
Resumen de: PL448505A1
Przedmiotem zgłoszenia jest kompozycja, sposób jej przygotowania oraz zastosowanie do zapobiegania zakażeniom koronawirusami, zwłaszcza SARS-CoV-2. Kompozycja w postaci wodnego koloidu zawiera w składzie 10% ektoinę oraz 0,1% hydroksyfuleren C60(OH)40 zmieszane w stosunku objętościowym 2:1. Preparat nanosi się na komórki nabłonka nosa narażone na kontakt z białkiem otoczki wirusa. Celem nanoszenia preparatu jest utworzenie stabilnej i przepuszczającej powietrze powłoki ochronnej, która wykazuje właściwości barierowe i pułapkowania w płaszczu wodnym i wirusobójcze wobec koronawirusów.
Resumen de: EP4647092A2
The devices and methods of the present invention can be used to capture and remove COVID-19 mediating nanoparticles and/or exosomes associated with COVID-19 or similar disease from the circulatory system of patients in need thereof, including those with post-COVID-19 syndrome or similar post-disease sequelae so-called "long haul" symptoms of COVID-19 or similar disease. The present invention directly benefits these patients by providing lectin based extracorporeal methods for binding and physically removing SARS-CoV-2 virions, or fragments thereof such as SARS-CoV-2-derived glycoproteins, from the circulatory system, thereby reducing viral load in infected blood. The present invention also provides lectin based extracorporeal methods of binding and physically removing non-viral COVID-19 mediating nanoparticles, such as exosomes containing SARS-CoV-2-derived glycoproteins and/or other biological molecules, including microRNAs, from the circulatory system, thereby reducing the severity of the disease or symptoms thereof. For patients severely affected by or at high risk for severe COVID-19 disease due to a SARS-CoV infection, the devices and methods of the present invention can be used to reduce time spent on mechanical ventilators, reduce the likelihood of cardiac complications, reduce the likelihood of multiorgan failure, reduce the likelihood of acute kidney disease, sepsis and/or other complications. Also disclosed herein are devices and methods for reducing the levels of b
Resumen de: US2025339508A1
Described herein are compositions of recombinant SARS-CoV-2 constructs and particles that can interfere with or block infection of uninfected cells. The compositions and methods described herein are useful for treatment of SARS-Co V-2 infections. The recombinant SARS-CoV-2 construct cannot replicate by itself, but can replicate in the presence of infective SARS-CoV-2 (e.g., replication competent SARS-CoV-2). Thus, the present application in one aspect provides a recombinant SARS-Co V-2 construct (e.g., SARS-CoV-2 TIP) capable of interfering with SARS-CoV-2 replication, wherein the recombinant SARS-CoV-2 construct cannot replicate by itself, and wherein the recombinant SARS-CoV-2 construct can replicate in the presence of SARS-CoV-2.
Resumen de: WO2025231018A2
Disclosed herein are capped RNA molecules comprising one or more modified nucleotides at position +3 or higher with reference to a 5' terminus of the RNA molecule, and methods of making the same. The capped RNA molecules may be made by ligating a 5'-capped modified RNA oligonucleotide to the 3' terminus of an RNA molecule. Also provided are compositions comprising one or more of the capped RNA molecules provided herein, and methods of using said compositions for therapeutic applications, such as in the treatment or prevention of a disease in a subject, such as SARS-CoV-2.
Resumen de: US2025340957A1
An oligonucleotide, having a 5′ terminus and a 3 terminus, wherein said oligonucleotide is detectably labeled and has a nucleotide sequence that consists essentially of one of the nucleotide sequences selected from SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:59, SEQ ID NO:60 and SEQ ID NO:77.
Resumen de: US2025341521A1
The present invention provides a novel method for the production of truly fully human monoclonal antibodies against SARS-CoV-2 using isolated human blood cells. These antigens may include but are not limited to peptide sequences found in envelope or spike proteins of SARS-CoV-2 proteins.
Resumen de: US2025339502A1
This disclosure is directed to compounds and pharmaceutical compositions for treating and preventing viral diseases, as Covid-19. Among others, the invention relates to the use of immune cells and ribonucleases in the preparation and use of pharmaceutical formulations for the treatment of said disease.
Resumen de: WO2025231364A1
The present disclosure relates to the field of vaccines, as well as preparations, articles of manufacture, and methods of their use in the treatment and/or prevention of diseases (e.g., infectious diseases, cancer, etc.). In certain embodiments, the disease is a coronavirus infection related disease. In certain embodiments, the coronavirus can be a P-coronaviruses (e.g., SARS- CoV-2).
Resumen de: WO2025231157A2
The application provides a plurality of new therapeutic peptides, which are designed based on the heptad repeat region of a viral spike fusion protein (such as SARS-Cov2, MERS-CoV, or HCov-OC43) or a heptad repeat region in a paramyxovirus (such as Measles, Nipah, or HPIV3) ), new therapeutic conjugates that comprising these therapeutic peptides, and methods of using the therapeutic peptide conjugates for the treatment of a condition or disease associated with a viral infection.
Resumen de: WO2025231155A2
The application provides a method to prevent or reduce the transmission of a coronavirus, such as a SARS- COV-2 variant, or a paramyxovirus from an infected subject to other uninfected subjects, comprising administrating an anti-viral peptide conjugate to the infected subject, the uninfected subject, or both.
Resumen de: WO2025231182A1
The application provides a pharmaceutical composition, which comprises an antiviral peptide conjugate, for the treatment or prevention of a condition or disease associated with a coronaviral infection. The coronavirus includes human coronavirus OC43, human coronavirus HKU1, human coronavirus 229E, human coronavirus NL63, Middle East respiratory syndrome-related coronavirus (MERS-CoV), SARS-CoV, SARS-CoV-2, or any variant thereof. The pharmaceutical composition is designed for, inter alia, intranasal administration.
Resumen de: WO2025230306A1
The present invention relates to a novel purine derivative compound and a composition for enhancing an immune response comprising same as an active ingredient. The compound of the present invention not only has a nanomolar EC50 value for TLR7, which is an intracellular membrane receptor of immune cells, but also has high selectivity for TLR7 compared to TLR8, which has a similar structure and is mainly distributed in the endoplasmic reticulum (ER), thereby being able to induce sustained immune activation. Therefore, the compound of the present invention can be effectively used as an efficient vaccine adjuvant composition against various RNA viruses including influenza virus, SARS-CoV-2, and hepatitis C virus.
Resumen de: WO2025230087A1
The present invention relates to an attenuated SARS-CoV-2 vaccine strain including nucleocapsid N gene transcriptional repression and a non-structural protein 1 (nsp1) protein mutation, and a use thereof. The attenuated SARS-CoV-2 vaccine strain according to the present invention has excellent safety and efficacy as a vaccine, and thus can be effectively used as an attenuated live vaccine for the prevention of coronavirus disease 2019.
Resumen de: WO2025227322A1
Provided are a broad-spectrum anti-COVID-19 vaccine immunogen composition, and the preparation and a use thereof. Specifically, provided is an immunogen composition, comprising an RBD recombinant chimeric antigen, wherein the chimeric antigen comprises S protein RBD domains from two or more COVID-19 subtypes, or functional fragments thereof. The immunogen composition can further comprise a multimerization domain and a T-cell immunogen domain. Further provided are a use of the immunogen composition, a corresponding encoding molecule therefor, a vector, and/or a host cell in preparing an anti-COVID-19 vaccine. The vaccine can induce a broad-spectrum protective effect against a prototype strain and various currently prevalent variants, and can also elicit a potent cross-protective T-cell response, thereby achieving effective and broad-spectrum prevention against COVID-19 and achieving a protective effect against other coronaviruses.
Resumen de: MX2025010057A
The present disclosure provides multivalent anti-spike protein binding molecules, comprising multimerization moieties linked to anti-spike protein antigen-binding domains, that specifically bind to RBD regions of SARS-CoV and/or SARS-CoV-2. The present disclosure further relates to the methods of producing the multivalent anti-spike protein binding molecules, pharmaceutical compositions comprising of the multivalent anti-spike protein binding molecules, and methods of use of the multivalent anti-spike protein binding molecules to treat conditions associated with SARS-CoV and SARS-CoV-2 infections, such as COVID-19.
Resumen de: MX2025010056A
The present disclosure provides multivalent anti-spike protein binding molecules. The present disclosure further relates to the methods of producing the multivalent anti-spike protein binding molecules, pharmaceutical compositions comprising of the multivalent anti-spike protein binding molecules, and methods of use of the multivalent anti-spike protein binding molecules, <i>e.g.</i>, to treat conditions associated with SARS-CoV and SARS-CoV-2 infections, such as COVID-19.
Nº publicación: MX2025012626A 03/11/2025
Solicitante:
NOVAVAX INC [US]
NOVAVAX, INC
Resumen de: MX2025012626A
Disclosed herein are coronavirus (CoV) Spike (S) polypeptides, including naturally and non-naturally occurring polypeptides, and nanoparticles and immunogenic compositions comprising the same, which are useful for stimulating immune responses against various SARS-CoV-2 strains. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
BOPI
Sede Electrónica
